Health TrialsbyHealthPanel

Gene Expression Analysis of Biofilm Formation and Antimicrobial Resistance in Clinical Methicillin-Resistant Staphylococcus Aureus

ConditionsStaphylococcal Aureus InfectionSurgical Site Infection (SSI)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-90
SponsorSohag University

About this trial

Staphylococcus aureus are Gram-positive cocci that asymptomatically colonize the skin and mucosal surfaces of approximately 20-30% of healthy individuals . Although they commonly exist as a harmless commensal organisms, S. aureus are one of the most clinically significant opportunistic pathogens, causing a wide range of community and healthcare-associated infections. These infections vary from superficial skin and soft tissue infections to severe invasive diseases, including bacteremia, infective endocarditis, pneumonia, osteomyelitis, and device-associated infections .

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients of any age diagnosed with postoperative SSIs.

Clinical isolates from SSIs identified as MRSA.

Disqualifiers

Any microorganism isolated from SSIs other than MRSA.

Prior administration of postoperative antibiotics

Trial population

wound swabs and pus specimens will be collected under complete aseptic conditions from patients with suspected SSIs using sterile swabs. The samples will be transferred immediately to the microbiology laboratory to be processed

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • swab from lesion

    Diagnostic test

    * Direct smear with Gram stain to identify the morphology of Staphylococcus aureus. * culture of the samples on different culture media such as nutrient agar, blood agar, and Mannitol salt agar.

  • Biochemical reactions

    Diagnostic test

    biochemical reactions: catalase test will be done to confirm diagnosis of Staphylococcus aureus.

  • Antibiotic sensitivity

    Diagnostic test

    Antibiotic sensitivity test will be done using different antibiotics according to CLSI 2026.

  • Molecular detection of antibiotic resistance

    Diagnostic test

    Assessment of the expression of selected biofilm-related genes (icaA and fnbA) and antibiotic resistance-related genes (mecA and femA) using quantitative real-time PCR (qRT-PCR) before and after treatment with probiotic cell-free supernatant (CFS).

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

The effect of Probiotic cell-free supernatant (CFS) on the expression of the biofilm-associated genes icaA and fnbA in clinical MRSA isolates..

Time frame
December 2026- to March 2027
2

The number of clinical Staphylococcus aureus isolates from SSIs and determine their antimicrobial susceptibility patterns to identify methicillin-resistant Staphylococcus aureus (MRSA).

Time frame
September 2026 to January 2027
3

The effect of Probiotic cell-free supernatant (CFS) on the expression of the antibiotic resistance-associated genes mecA and femA in clinical MRSA isolates

Time frame
March 2027 to June 2027

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sohag University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: